A Phase 2b, Randomized, Double blind, Placebo controlled, Parallel group, Multicenter, Dose ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants with Uncontrolled Moderate to Severe Eosinophilic Asthma
Spain, Romania, Slovakia, Poland, Germany, Italy, Belgium, Austria
Condition studied
Uncontrolled Moderate to Severe Eosinophilic Asthma
Investigational medicinal product(s)
KT-621KT-621KT-621Placebo oral tablet matched to KT-621
Eligibility
Age group
18-64 years, 65+ years
Sex
Female, Male
Primary endpoint
Change from baseline to Week 12 in pre-bronchodilator FEV1.
Endpoint detail
Change from baseline to Week 12 in post-bronchodilator FEV1., Change from baseline to Week 12 in ACQ-5 score, Change from baseline to Week 12 in the AQLQ(S) Global Score, Incidence of TEAEs, Incidence of treatment-emergent SAEs, Plasma PK parameter estimates of KT-621 derived from plasma concentration time data
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.